A novel fat-burning injection has shown promise in aiding weight loss while allowing individuals to maintain their usual food intake. Animal studies indicate that the experimental drug, RES-010, enhances food metabolism, preventing excess storage as fat. Mice treated with the weekly injection exhibited weight loss despite consuming the same amount of food as untreated mice.
Preliminary research presented at the European Association for the Study of Diabetes meeting in Vienna revealed that mice did not regain weight post-treatment cessation. Unlike existing weight loss injections that curb appetite, this injection targets an RNA molecule, miR-22, known as a pivotal regulator in obesity-related processes.
The injection’s mechanism involves reprogramming cells to optimize fat and energy utilization, increase mitochondrial production and activity, and convert white fat into brown fat for energy expenditure. The drug, RES-010, aims to provide sustainable weight loss and metabolic benefits by modifying the body’s metabolism, potentially improving liver health.
While initial results are promising, further evidence is required to substantiate the drug’s efficacy. Dr. Adam Collins, an associate professor of nutrition at the University of Surrey, emphasized the necessity of comprehending the drug’s mechanisms and metabolic effects before drawing definitive conclusions on weight loss outcomes.
Appetite-suppressing injections like Mounjaro and Wegovy have been recognized as valuable tools in combating obesity, particularly within the NHS. However, due to global shortages, these injections are primarily accessible through private prescriptions, limiting the NHS’s ability to offer them to all eligible individuals. Weight loss injections require comprehensive support in diet and lifestyle modifications to enhance effectiveness and prevent weight regain.
Studies suggest that users of GLP-1 injections may experience muscle loss in addition to fat reduction. Without sustained dietary and activity adjustments, individuals may regain fat but not muscle mass upon discontinuation of these injections.